- Live Vaccines
- Attenuated Vaccines
The global Shingles Vaccine Market is expected to grow at a CAGR of 9.3% during the forecast period 2022 to 2028. Shingles is known as Herpes Zoster which causes a blistering painful rash on the skin which lasts from 2 to 4 weeks. But, for some people, the pain may last for months or years. This pain is called as (PHN) Post Herpetic Neuralgia, which is common complication of shingles and it’s occurrence increases with age. There are safe and effective vaccines are available for prevention of shingles. In 2006, Merck & Co., Inc. licenced Zostavax for prevention of shingles which is intended for people above 50years of age. In 2016, GSK received FDA approval for its Shingrix, vaccine to prevent shingles which has 90% efficiency in people than zostavax. GSK filed regulatory approvals in Europe, Canada and Japan for Shingrix. Shingles vaccine market is a very high consolidated market with very few market players. It is experiencing a rapid growth due to the new products and it may gain swift in market growth due to the new entrants into the market during the forecast period. One key aspect contributing to the global market's overall growth is the increasing number of official recommendations to use these vaccinations. Furthermore, the growing number of senior individuals is predicted to fuel an ever-expanding industry. Many firms have spent a significant amount of money on research and development in order to create new shingles vaccines. This also contributes to a rise in the number of new product approvals by the FDA. The dangers linked with the vaccine's side effects, on the other hand, are extremely substantial. Furthermore, in the poor countries, there is a lack of understanding about supply and use of these products. In the years ahead, it is possible to pose a threat to the Shingles Vaccine Market's growth.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the prevalence and incidence of shingles disease around the world and increase in the global ageing population is expected to enhance the growth of shingles vaccine market across the globe. But, lack of awareness, high cost of the vaccination, unfavourable insurance coverage is major restraints of the global shingles vaccine market.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary |
2. Global Shingles Vaccine Market Introduction |
2.1. Global Shingles Vaccine Market – Taxonomy |
2.2. Global Shingles Vaccine Market –Definitions |
2.2.1. By Product Type |
2.2.2. By Vaccine Type |
2.2.3. By Region |
3. Global Shingles Vaccine Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Shingles Vaccine Market Dynamic Factors - Impact Analysis |
3.6. Impact of COVID-19 on The Market |
3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
3.8. Mapping Market Players’ Activities |
3.9. Recent Key Developments |
3.10. Financial Status of the Market Players |
3.11. Recent Acquisitions, Collaborations, and Mergers |
4. Global Shingles Vaccine Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 |
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Shingles Vaccine Market Forecast, By Product Type, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.1. Shingrix |
5.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Zostavax |
5.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. SKYZoster |
5.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Shingles Vaccine Market Forecast, By Vaccine Type, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
6.1. Recombinant Vaccine |
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Live Attenuated Vaccine |
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Shingles Vaccine Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia-Pacific |
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Middle East and Africa |
7.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Global Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Distribution Channel, Vaccine Type, and Region, 2022 - 2028 |
8. North America Shingles Vaccine Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
8.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Shingrix |
8.1.2. Sheath |
8.1.3. SKYZoster |
8.1.4. Others |
8.2. Vaccine Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
8.2.1. Recombinant Vaccine |
8.2.2. Live Attenuated Vaccine |
8.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
8.3.1. U.S. |
8.3.2. Canada |
8.4. North America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2022 - 2028 |
8.5. North America Shingles Vaccine Market Dynamics – Trends |
9. Europe Shingles Vaccine Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
9.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Shingrix |
9.1.2. Sheath |
9.1.3. SKYZoster |
9.1.4. Others |
9.2. Vaccine Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Recombinant Vaccine |
9.2.2. Live Attenuated Vaccine |
9.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Germany |
9.3.2. UK |
9.3.3. France |
9.3.4. Italy |
9.3.5. Spain |
9.3.6. Rest of Europe |
9.4. Europe Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2022 - 2028 |
9.5. Europe Shingles Vaccine Market Dynamics – Trends |
10. Asia-Pacific Shingles Vaccine Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
10.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Shingrix |
10.1.2. Sheath |
10.1.3. SKYZoster |
10.1.4. Others |
10.2. Vaccine Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Recombinant Vaccine |
10.2.2. Live Attenuated Vaccine |
10.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Japan |
10.3.2. China |
10.3.3. India |
10.3.4. ASEAN |
10.3.5. Rest of Asia-Pacific |
10.4. Asia-Pacific Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2022 - 2028 |
10.5. Asia-Pacific Shingles Vaccine Market Dynamics – Trends |
11. Latin America Shingles Vaccine Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
11.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Shingrix |
11.1.2. Sheath |
11.1.3. SKYZoster |
11.1.4. Others |
11.2. Vaccine Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Recombinant Vaccine |
11.2.2. Live Attenuated Vaccine |
11.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Brazil |
11.3.2. Argentina |
11.3.3. Rest of Latin America |
11.4. Latin America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2022 - 2028 |
11.5. Latin America Shingles Vaccine Market Dynamics – Trends |
12. Middle East and Africa Shingles Vaccine Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
12.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Shingrix |
12.1.2. Sheath |
12.1.3. SKYZoster |
12.1.4. Others |
12.2. Vaccine Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Recombinant Vaccine |
12.2.2. Live Attenuated Vaccine |
12.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Saudi Arabia |
12.3.2. GCC Countries |
12.3.3. South Africa |
12.3.4. Rest of MEA |
12.4. MEA Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2022 - 2028 |
12.5. MEA Shingles Vaccine Market Dynamics – Trends |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. GlaxoSmithKline plc. |
13.2.2. Merck & Co., Inc. |
13.2.3. SK chemicals |
13.2.4. Green Cross Corp |
13.2.5. CanSinoBIO |
13.2.6. Geneone Life Science |
13.2.7. Vaccitech |
13.2.8. Curevo Inc |
14. Research Methodology |
15. Key Assumptions and Acronyms |